RNS Number : 3517H
N4 Pharma PLC
03 December 2020

3 December 2020

N4 Pharma plc
("**N4 Pharma**" or the "**Company**")

Formulation Work Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide the following update on its ongoing research collaboration agreement with Nanomerics Limited ("Nanomerics").

As announced on 11 February 2020, the Company initiated the first phase of research to test the stability of different formulations of Nuvec® loaded with a well characterised plasmid DNA. The Company is pleased to report that, in addition to not degrading the plasmid DNA, which it announced on 5 November 2020, Nuvec® formulations that had been freeze dried and then stored for 14 days either at room temperature or at four degrees Celsius, showed no significant drop in *in vitro* transfection capability following reconstitution compared to fresh formulations.

In parallel to continued work on analysing stability duration, different formulations will now be chosen to move forward into phase two of the work programme testing the efficacy of the dried and reconstituted plasmid DNA in an *in vivo* antibody generation model.

Nigel Theobald, Chief Executive Officer of the Company, commented:

"Demonstrating that Nuvec® loaded with a plasmid DNA can be dried, stored at convenient temperatures and reconstituted without any drop in transfection is a significant step forward in our formulation development work.

"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines. However, it also highlights that these vaccines have certain limitations, in that they often require extreme storage conditions.

"Although vaccine efficacy is predominantly determined by the selected nucleic acid antigen, having a stable, easy to store and easy to use vaccine is

crucial in helping vaccine acceptance and uptake. A formulation stable at room temperature or even refrigerated can represent significant cost savings in vaccine transportation, storage and administration. We believe, to the extent that Nuvec® as a delivery platform can provide a solution in this area, it could be of significant interest to multiple vaccine developers.

"Work will continue in this area and will add to the breadth of proof of concept data we are building for the use of Nuvec® as a delivery system for vaccines and cancer treatments."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

Enquiries:

N4 Pharma plc

Nigel Theobald, CEO — Via IFC Advisory

Luke Cairns, Executive Director

SP Angel Corporate Finance LLP — Tel: +44(0)20 3470 0470

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited — Tel: +44(0)20 3657 0050

Joint Broker

Andy Thacker

IFC Advisory Ltd — Tel: +44(0)20 3934 6630

Financial PR

Graham Herring

Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the

required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive up-front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBCBDDUBGDGGD